CDTX Research and Charts

CDTX - Cidara Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-06)

Last 26.81	Change ⇑ +0.19 (+0.71%)	Volume 171,467
	Open 26.57	High 26.96	Low 25.11

8EMA (Daily) 25.64	40EMA (Daily) 20.91	50EMA (Daily) 19.89	STO (Daily) 88.550	MACD Hist (Daily) 0.399
8EMA (Weekly) 23.010	40EMA (Weekly) 14.28	50EMA (Weekly) 12.84	STO (Weekly) 90.518	MACD Hist (Weekly) 2.023


Company Profile
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.